liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Epstein–Barr virus in bone marrow of rheumatoidarthritis patients predicts response to rituximabtreatment
Linköping University, Department of Clinical and Experimental Medicine, Division of Inflammation Medicine. Sahlgrenska University Hospital, Göteborg, Sweden.
Sahlgrenska University Hospital, Göteborg, Sweden.
Sahlgrenska University Hospital, Göteborg, Sweden.
Sahlgrenska University Hospital, Göteborg, Sweden.
Show others and affiliations
2010 (English)In: British Journal of Rheumatology, ISSN 0263-7103, E-ISSN 1460-2172, Vol. 49, 1911-1919 p.Article in journal (Refereed) Published
Abstract [en]


Objectives. Viruses may contribute to RA. This prompted us to monitor viral load and response to anti-CD20 therapy in RA patients.

Methods. Blood and bone marrow from 35 RA patients were analysed for CMV, EBV, HSV-1, HSV-2, parvovirus B19 and polyomavirus using real-time PCR before and 3 months after rituximab (RTX) treatment and related to the levels of autoantibodies and B-cell depletion. Clinical response to RTX was defined as decrease in the 28-joint disease activity score (DAS-28) >1.3 at 6 months.

Results. Before RTX treatment, EBV was identified in 15 out of 35 patients (EBV-positive group), of which 4 expressed parvovirus. Parvovirus was further detected in eight patients (parvo-positive group). Twelve patients were negative for the analysed viruses. Following RTX, EBV was cleared, whereas parvovirus was unaffected. Eighteen patients were responders, of which 12 were EBV positive. The decrease in the DAS-28 was significantly higher in EBV-positive group compared with parvo-positive group (P = 0.002) and virus-negative patients (P = 0.04). Most of EBV-negative patients that responded to RTX (75%) required retreatment within the following 11 months compared with only 8% of responding EBV-positive patients. A decrease of RF, Ig-producing cells and CD19+ B cells was observed following RTX but did not distinguish between viral infections. However, EBV-infected patients had significantly higher levels of Fas-expressing B cells at baseline as compared with EBV-negative groups.

Conclusions. EBV and parvovirus genomes are frequently found in bone marrow of RA patients. The presence of EBV genome was associated with a better clinical response to RTX. Thus, presence of EBV genome may predict clinical response to RTX.

Place, publisher, year, edition, pages
2010. Vol. 49, 1911-1919 p.
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-65518DOI: 10.1093/rheumatology/keq159OAI: diva2:396210
Available from: 2011-02-09 Created: 2011-02-09 Last updated: 2014-12-03

Open Access in DiVA

fulltext(436 kB)37 downloads
File information
File name FULLTEXT01.pdfFile size 436 kBChecksum SHA-512
Type fulltextMimetype application/pdf

Other links

Publisher's full text

Search in DiVA

By author/editor
Magnusson, Mattias
By organisation
Division of Inflammation Medicine
In the same journal
British Journal of Rheumatology
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
Total: 37 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 82 hits
ReferencesLink to record
Permanent link

Direct link